Arcturus Therapeutics (ARCT) Misses Q2 EPS by $3.55

Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($0.34), $3.55 worse than the analyst estimate of $3.21. Revenue for the quarter came in at $0 versus the consensus estimate of $191.77 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• ResMed names Carol Burt as lead director as Ron Taylor retires
• Micron Technology (MU) call put ratio 1.4 calls to 1 put on 1.2M contracts as share price up 4%